Why the study?
Although applied in vitro and in selected clinical cases, a systematic clinical validation of 3D high-pulse repetition frequency Doppler for valvular regurgitation volume estimation had not been published.
Does 3D high-pulse repetition frequency Doppler echocardiography accurately and feasibly quantify regurgitant volume compared to PISA and CMR in patients with aortic or mitral regurgitation?
Does 3D high-pulse repetition frequency Doppler echocardiography accurately and feasibly quantify regurgitant volume compared to PISA and CMR in patients with aortic or mitral regurgitation?
3D HPRFD has low feasibility and correlates poorly with established methods (PISA and CMR) for quantifying valvular regurgitation, indicating it is not ready for clinical use.
Answers are grounded in this paper and cite their sources.
3D HPRFD feasibility remains low (44-56%), especially in severe regurgitation; leaves open its clinical role pending technical advances and larger validation.
Aims To improve quantification of valvular regurgitation, a 3D high-pulse repetition frequency Doppler (3D HPRFD) method was developed for regurgitant volume (RVol) estimation from transthoracic echocardiography (TTE). Although successfully applied in vitro and in selected clinical cases, a systematic clinical validation of 3D HPRFD has not been published. Hence, our aims were to investigate (i) feasibility of 3D HPRFD and (ii) correlation between 3D HPRFD and RVol estimates obtained by the 2D proximal isovelocity surface area (PISA) method and cardiac magnetic resonance (CMR) in patients with either aortic regurgitation (AR) or mitral regurgitation (MR). Methods and results We included 45 patients with AR (42% mild, 40% moderate, and 18% severe) and 45 with MR (67% mild, 24% moderate, and 9% severe). Median time between start of TTE and start of CMR was 1.5 h, minimizing changes in load. Overall feasibility of 3D HPRFD was 56% in AR and 44% in MR. Feasibility was only 25% in patients with severe regurgitation. In AR, estimated RVol from 3D HPRF did not correlate with estimated RVol from PISA or CMR [Spearman rho = 0.06 (P = 0.78) and 0.04 (P = 0.4), respectively]. In MR, RVol estimates from 3D HPRFD correlated with PISA (rho = 0.72, P < 0.001) but not with CMR (rho = 0.31, P = 0.43). Conclusion Regurgitant volume estimation by 3D HPRFD had a low feasibility, especially in severe regurgitation, and in general correlated poorly with PISA and CMR estimates. In its current state, 3D HPRFD is not ready for clinical use.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: